Raloxifene and Desmethylarzoxifene Block Estrogen-induced Malignant Transformation of Human Breast Epithelial Cells

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2011 Dec 6

PMID 22140478

Citations 7

Authors

Irida Kastrati

Praneeth D Edirisinghe

L-P-Madhubani P Hemachandra

Esala R Chandrasena

Jaewoo Choi

Yue-Ting Wang

Judy L Bolton

Gregory R J Thatcher

Affiliations

Soon will be listed here.

Abstract

There is association between exposure to estrogens and the development and progression of hormone-dependent gynecological cancers. Chemical carcinogenesis by catechol estrogens derived from oxidative metabolism is thought to contribute to breast cancer, yet exact mechanisms remain elusive. Malignant transformation was studied in MCF-10A human mammary epithelial cells, since estrogens are not proliferative in this cell line. The human and equine estrogen components of estrogen replacement therapy (ERT) and their catechol metabolites were studied, along with the influence of co-administration of selective estrogen receptor modulators (SERMs), raloxifene and desmethyl-arzoxifene (DMA), and histone deacetylase inhibitors. Transformation was induced by human estrogens, and selectively by the 4-OH catechol metabolite, and to a lesser extent by an equine estrogen metabolite. The observed estrogen-induced upregulation of CYP450 1B1 in estrogen receptor negative MCF-10A cells, was compatible with a causal role for 4-OH catechol estrogens, as was attenuated transformation by CYP450 inhibitors. Estrogen-induced malignant transformation was blocked by SERMs correlating with a reduction in formation of nucleobase catechol estrogen (NCE) adducts and formation of 8-oxo-dG. NCE adducts can be formed consequent to DNA abasic site formation, but NCE adducts were also observed on incubation of estrogen quinones with free nucleotides. These results suggest that NCE adducts may be a biomarker for cellular electrophilic stress, which together with 8-oxo-dG as a biomarker of oxidative stress correlate with malignant transformation induced by estrogen oxidative metabolites. The observed attenuation of transformation by SERMs correlated with these biomarkers and may also be of clinical significance in breast cancer chemoprevention.

Citing Articles

Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.

Lu Y, Gutgesell L, Xiong R, Zhao J, Li Y, Rosales C J Med Chem. 2019; 62(24):11301-11323.

PMID: 31746603 PMC: 7261373. DOI: 10.1021/acs.jmedchem.9b01580.

Carvedilol suppresses malignant proliferation of mammary epithelial cells through inhibition of the ROS‑mediated PI3K/AKT signaling pathway.

Ma Z, Liu X, Zhang Q, Yu Z, Gao D Oncol Rep. 2018; 41(2):811-818.

PMID: 30483797 PMC: 6312993. DOI: 10.3892/or.2018.6873.

Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer.

Xiong R, Zhao J, Gutgesell L, Wang Y, Lee S, Karumudi B J Med Chem. 2017; 60(4):1325-1342.

PMID: 28117994 PMC: 5786431. DOI: 10.1021/acs.jmedchem.6b01355.

Estrogen Drives Cellular Transformation and Mutagenesis in Cells Expressing the Breast Cancer-Associated R438W DNA Polymerase Lambda Protein.

Nemec A, Bush K, Towle-Weicksel J, Taylor B, Schulz V, Weidhaas J Mol Cancer Res. 2016; 14(11):1068-1077.

PMID: 27621267 PMC: 5107123. DOI: 10.1158/1541-7786.MCR-16-0209.

Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer.

Xiong R, Patel H, Gutgesell L, Zhao J, Delgado-Rivera L, Pham T J Med Chem. 2015; 59(1):219-237.

PMID: 26681208 PMC: 4779956. DOI: 10.1021/acs.jmedchem.5b01276.

References

Ravdin P, Cronin K, Howlader N, Berg C, Chlebowski R, Feuer E . The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007; 356(16):1670-4. DOI: 10.1056/NEJMsr070105. View

Tait L, SOULE H, Russo J . Ultrastructural and immunocytochemical characterization of an immortalized human breast epithelial cell line, MCF-10. Cancer Res. 1990; 50(18):6087-94. View

Jackson A, Loeb L . The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. Mutat Res. 2001; 477(1-2):7-21. DOI: 10.1016/s0027-5107(01)00091-4. View

Shin S, Freedman V, Risser R, Pollack R . Tumorigenicity of virus-transformed cells in nude mice is correlated specifically with anchorage independent growth in vitro. Proc Natl Acad Sci U S A. 1975; 72(11):4435-9. PMC: 388736. DOI: 10.1073/pnas.72.11.4435. View

Lareef M, Garber J, Russo P, Russo I, Heulings R, Russo J . The estrogen antagonist ICI-182-780 does not inhibit the transformation phenotypes induced by 17-beta-estradiol and 4-OH estradiol in human breast epithelial cells. Int J Oncol. 2005; 26(2):423-9. View

Miller E, Miller J . Mechanisms of chemical carcinogenesis. Cancer. 1981; 47(5 Suppl):1055-64. DOI: 10.1002/1097-0142(19810301)47:5+<1055::aid-cncr2820471302>3.0.co;2-3. View

Chen Z, Hurh Y, Na H, Kim J, Chun Y, Kim D . Resveratrol inhibits TCDD-induced expression of CYP1A1 and CYP1B1 and catechol estrogen-mediated oxidative DNA damage in cultured human mammary epithelial cells. Carcinogenesis. 2004; 25(10):2005-13. DOI: 10.1093/carcin/bgh183. View

Qin Z, Kastrati I, Chandrasena R, Liu H, Yao P, Petukhov P . Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity. J Med Chem. 2007; 50(11):2682-92. DOI: 10.1021/jm070079j. View

Lu F, Zahid M, Wang C, Saeed M, Cavalieri E, Rogan E . Resveratrol prevents estrogen-DNA adduct formation and neoplastic transformation in MCF-10F cells. Cancer Prev Res (Phila). 2009; 1(2):135-45. PMC: 4424907. DOI: 10.1158/1940-6207.CAPR-08-0037. View

10.

Cuendet M, Liu X, Pisha E, Li Y, Yao J, Yu L . Equine estrogen metabolite 4-hydroxyequilenin induces anchorage-independent growth of human mammary epithelial MCF-10A cells: differential gene expression. Mutat Res. 2004; 550(1-2):109-21. DOI: 10.1016/j.mrfmmm.2004.02.005. View

11.

Cummings S, McClung M, Reginster J, Cox D, Mitlak B, Stock J . Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J Bone Miner Res. 2010; 26(2):397-404. DOI: 10.1002/jbmr.191. View

12.

Liu H, Liu J, van Breemen R, Thatcher G, Bolton J . Bioactivation of the selective estrogen receptor modulator desmethylated arzoxifene to quinoids: 4'-fluoro substitution prevents quinoid formation. Chem Res Toxicol. 2005; 18(2):162-73. DOI: 10.1021/tx049776u. View

13.

Cavalieri E, Stack D, Devanesan P, Todorovic R, Dwivedy I, Higginbotham S . Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc Natl Acad Sci U S A. 1997; 94(20):10937-42. PMC: 23537. DOI: 10.1073/pnas.94.20.10937. View

14.

Liehr J . Is estradiol a genotoxic mutagenic carcinogen?. Endocr Rev. 2000; 21(1):40-54. DOI: 10.1210/edrv.21.1.0386. View

15.

Lu F, Zahid M, Saeed M, Cavalieri E, Rogan E . Estrogen metabolism and formation of estrogen-DNA adducts in estradiol-treated MCF-10F cells. The effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin induction and catechol-O-methyltransferase inhibition. J Steroid Biochem Mol Biol. 2007; 105(1-5):150-8. PMC: 1986824. DOI: 10.1016/j.jsbmb.2006.12.102. View

16.

Yu B, Qin Z, Wijewickrama G, Edirisinghe P, Bolton J, Thatcher G . Comparative methods for analysis of protein covalent modification by electrophilic quinoids formed from xenobiotics. Bioconjug Chem. 2009; 20(4):728-41. PMC: 2827204. DOI: 10.1021/bc800435m. View

17.

Saeed M, Higginbotham S, Rogan E, Cavalieri E . Formation of depurinating N3adenine and N7guanine adducts after reaction of 1,2-naphthoquinone or enzyme-activated 1,2-dihydroxynaphthalene with DNA. Implications for the mechanism of tumor initiation by naphthalene. Chem Biol Interact. 2007; 165(3):175-88. DOI: 10.1016/j.cbi.2006.12.007. View

18.

Shen L, Pisha E, Huang Z, Pezzuto J, Krol E, Alam Z . Bioreductive activation of catechol estrogen-ortho-quinones: aromatization of the B ring in 4-hydroxyequilenin markedly alters quinoid formation and reactivity. Carcinogenesis. 1997; 18(5):1093-101. DOI: 10.1093/carcin/18.5.1093. View

19.

Conzen S . Current status of selective estrogen receptor modulators (SERMs). Cancer J. 2003; 9(1):4-14. DOI: 10.1097/00130404-200301000-00003. View

20.

Beis I, Newsholme E . The contents of adenine nucleotides, phosphagens and some glycolytic intermediates in resting muscles from vertebrates and invertebrates. Biochem J. 1975; 152(1):23-32. PMC: 1172435. DOI: 10.1042/bj1520023. View